It’s because the company is considering the curr

It’s because the company is considering the current hold to be an extension of the first in regards to PR’s. Clearly they are ok signing deals like the AI company and JL’s father’s trial for glioblastoma. But they aren’t yet ready to PR things out of caution. I’d wager they could have at least PR’d the glio trial, but they clearly think differently. And since they are the ones speaking with the fda consistently since the first hold began I’m fine with their strategy in regards to caution. The trial protocol being accepted should open the flood gates. It’s annoying, but announcing the hold lift and not announcing the protocol hold might have irked the fda, and announcing both would have been a bad idea.